Discounted Cash Flow (DCF) Analysis Unlevered
Aeglea BioTherapeutics, Inc. (AGLE)
$0.1271
+0.00 (+0.87%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 3.89 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -44.06 | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | ||||||||||
| EBIT | -44.35 | - | - | - | - | - | - | - | - | - |
| EBIT (%) | ||||||||||
| Depreciation | 0.29 | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | 74.51 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | - | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | 0.66 | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | -0.42 | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.1,271 |
|---|---|
| Beta | 1.748 |
| Diluted Shares Outstanding | 84.28 |
| Cost of Debt | |
| Tax Rate | 0.16 |
| After-tax Cost of Debt | 18.05% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 12.041 |
| Total Debt | 4.63 |
| Total Equity | 10.71 |
| Total Capital | 15.34 |
| Debt Weighting | 30.17 |
| Equity Weighting | 69.83 |
| Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 3.89 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -44.06 | - | - | - | - | - | - | - | - | - |
| EBIT | -44.35 | - | - | - | - | - | - | - | - | - |
| Tax Rate | 0.00% | 0.00% | 0.00% | -0.21% | 0.16% | -0.01% | -0.01% | -0.01% | -0.01% | -0.01% |
| EBIAT | -44.35 | - | - | - | - | - | - | - | - | - |
| Depreciation | 0.29 | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -0.42 | -1.49 | -4.28 | -0.57 | -0.04 | - | - | - | - | - |
| UFCF | -44.48 | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | - | - | - | - | |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 13.85 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -30.23 |
| Equity Value | - |
| Shares Outstanding | 84.28 |
| Equity Value Per Share | - |